Kornimate/medical-research-clean huggingface dataset:
engaging siblings of adults with autism in future planning

Conditions: Autistic Disorder

Summary: the goal of this pilot study was to develop and obtain preliminary feasibility and effectiveness data of a telehealth program (siblings forward) to help siblings of autistic adults work with their families to plan for the future. the main questions it aimed to answer were: * is the siblings forward program feasible to implement via telehealth in the community setting? * do siblings benefit from participation in the siblings forward program? the siblings forward program involves 6-7 individualized telehealth sessions with a trained community facilitator. researchers compared participation in the siblings forward program to an information-only control condition.

the researchers developed a program to facilitate the engagement of adult siblings to work with their families to plan for the future of their autistic sibling. siblings forward (focusing on relationships, well-being, and responsibility ahead) targeted common barriers to sibling involvement in family future planning, including improving family communication around difficult topics, increasing siblings' knowledge of and confidence in accessing autism service systems, and anticipating and proactively problem-solving barriers to future planning. the siblings forward program was developed in collaboration with community organizations, with input from siblings, autistic adults, and community providers. siblings forward was implemented in a community setting, with trained program facilitators. a small randomized controlled trial tested participation in siblings forward compared to information about services only.

Eligibility criteria:
inclusion criteria: siblings of adults with autism spectrum disorder (asd): * have one or more adult brother(s) or sister(s) with asd who are either biologically related and/or were raised in the same family of origin (e.g., adopted, step, or foster siblings) * age 18+. * english or spanish fluency. autistic adults: * have an asd diagnosis. * have an adult sibling * age 21+. * english or spanish fluency if verbal. exclusion criteria: siblings of autistic adults: -siblings will be excluded if they have an asd diagnosis themselves or if they have any disability that would interfere with their ability to engage meaningfully in future planning for the autistic adult. autistic adults: -none
eus-fna of solid pancreatic mass: comparison between negative pressure and slow-pull technique

Conditions: Pancreatic Neoplasm

Summary: 50 patients with pancreatic mass will undergo endoscopic ultrasound-guided fine needle aspiration using two techniques: negative pressure and slow-pull. cytological results will be compared.

the study will analyze the cytological results of endoscopic ultrasound-guided fine needle aspiration (eus-fna) of pancreatic mass using two different techniques of needle suction. negative pressure and slow-pull. 50 patients with pancreatic mass will be submitted to four passes with both techniques. each patient will be randomized to decide which technique will be first and subsequently on a alternated fashion until four passes are completed. smear cytology and cell block preparations for each technique were obtained. the pathologist was blinded for the eus-fna technique.

Eligibility criteria:
inclusion criteria: * pancreatic solid mass exclusion criteria: * endoscopic ultrasound non accessible lesions

Keywords: eus-fna pancreatic neoplasm slow-pull negative pressure
blood pressure variability and cardiovascular disease events in patients with hypertension

Conditions: Blood Pressure Variability; Hypertension; Cardiovascular Diseases

Summary: cardiovascular disease (cv) including stroke is the leading cause of death in malaysia hypertension is a major contributor to this. prevalence of hypertension in malaysia is high (42%) in adults age 30 years or older. besides the actual blood pressure (bp) level recently, blood pressure variability (bpv) has been recognized as an independent and strong predictor of cv events especially strokes. however, data on the bp variability and its relationship to cv events is very limited in asia, particularly in malaysia. hence the investigators aim to study bpv and its relationship to cv events in treated hypertensive patients

this will be a cross-sectional study on patients with hypertension. the 10-year retrospective data on bp, treatment, biochemical changes, kidney function and cv events will be extracted from patient records. eligible patients who have given written informed consent will be given a questionnaire capturing data of their socio-demographic status, weight, height and bp measured. those agreeable to measure their own bp at home 3 times a day for a week will be loaned a bp device to measure their own bp at home. the home bp readings will be recorded onto a provided form and returned to the investigators. data will be analysed to 1. determine bpv of the clinic visit-to-visit bpv (long tem bpv) 2. determine the day to day bpv (short term bpv) 3. examine the bpv to cv events, kidney function, cognition 4. determine the prevalence of white coat and masked hypertension 5. determine the level of control of bp 6. examine the relationship of ownership of home bp devices to control and satisfaction of treatment

Eligibility criteria:
inclusion criteria: * patients on treatment for hypertension of at least 3 years * patients who consent to the study exclusion criteria: * those unable to give consent * recent (less than 6 months) of cardiovascular events (stroke, heart attack, heart failure) * patients on dialysis * patients with end stage kidney failure

Keywords: blood pressure variability hypertension cardiovascular diseases
impact of community scabies treatment on head lice prevalence in the solomon islands

Conditions: Scabies; Head Lice

Summary: this is a pilot study evaluating if treatment for scabies also treats headlice in the same community

background: scabies and head lice are both ubiquitous ectoparasitic infections that have been identified as common public health problems in the pacific island country territories. mass drug administration using ivermectin is increasingly recognised as an effective strategy for scabies treatment and control, however, its possible impact on prevalence of head lice has not been evaluated. given that oral ivermectin is an effective treatment option for pediculosis capitis, we hypothesise that community treatment with ivermectin for scabies would also provide benefit by reducing prevalence of head lice infestation in the community. we aim to test this hypothesis with a small-scale pilot study in the solomon islands. methodology: the study would be carried out at the atoifi adventist hospital campus, on the north-eastern coast of the island of malaita. the campus houses an estimated 180 individuals and all residents would be invited to participate in the study and be offered treatment. at baseline all individuals would undergo a standardized examination to collect data on the presence of scabies, impetigo and head lice. following examination individuals would be weighed and given directly observed standard treatment for scabies. treatment for scabies consists of one oral dose of ivermectin (200 micrograms per kilogram) at day 1 and at day 8. individuals with contra-indications (pregnancy, breast feeding, weight under 15kg) would be offered the alternative of 5% permethrin cream and malathion shampoo. individuals would be re-examined at 48hours (to assess immediate killing of head lice) and again at 2 weeks. final follow-up will be at 3 months to establish: 1) whether changes in head lice prevalence have been sustained 2) what the impact of treatment on scabies and impetigo with ivermectin is in this specific community.

Eligibility criteria:
inclusion criteria: * all participants living in the community will be offered treatment exclusion criteria: * patients with a contradindication to study medication * patients unable to provide consent
the influence of biologcal treatment on the short-term complications of surgery in patients with inflematory bowel disease.

Conditions: Ulcerative Colitis; Anti TNF Therapy; Ileal Pouch Anal Anastomosis (IPAA)

Summary: background: previous studies of short-term surgical outcomes after preoperative exposure to anti-tnf therapy in ulcerative colitis (uc) patients who have undergone ipaa have been conflicting. we sought to determine whether preoperative exposure to anti-tnf therapy affects histological measures of fibrosis in the colorectum, which may be a potential factor in adverse anastomosis complications following ipaa surgery. methods: individuals who received infliximab as maintenance therapy and who received their last dose within 180 days of the first stage of ipaa were selected. the control group comprised uc patients who were not exposed to anti-tnf therapy, matched by age, sex, bmi, disease duration, albumin levels, and post-operative leak outcome. hematoxylin and eosin- (h\&e) and trichrome-stained slides from the most distal, well-oriented, full-thickness section of colorectum from each patient's total colectomy specimen were evaluated. blinded assessment of the degree of fibrosis in the lamina propria, the submucosa, the submucosa immediately adjacent to the muscularis propria, and the subserosa was performed by a single observer using a semi-quantitative pictorial scale.


Eligibility criteria:
inclusion criteria: * all individuals with ibd who underwent ipaa from january 2002 to june 2013 were reviewed . exclusion criteria: * patients with cd * patients without adequate clinical records documenting the 30-day postoperative clinical outcomes .
menthol flavored e-cigarette use during a simulated ban of menthol cigarettes

Conditions: Tobacco Use Disorder

Summary: the purpose of this formative study is to provide preliminary data regarding how the availability of menthol flavored e-cigarettes affects tobacco use behavior in the context of a ban on menthol flavored cigarettes


Eligibility criteria:
inclusion criteria: * self identify as african american * smoke primarily menthol cigarettes * be between the ages of 18 and 64 * smoke a minimum number of cigarettes per day * agree to abstain from menthol cigarettes for an 8 week period exclusion criteria: * current unstable medical / psychiatric condition * regular use any form of nicotine or tobacco other than cigarettes * are pregnant or breast feeding the investigators will evaluate if there are other reasons why someone may not be eligible to participate
developing mouse models of breast cancer using tissue samples from women with breast cancer

Conditions: Breast Cancer

Summary: rationale: changing the genes in laboratory mice to create a living model of human breast cancer may help doctors learn more about breast cancer. purpose: this research study is developing mouse models of breast cancer using tissue samples that were previously collected from women with breast cancer.

objectives: * to develop new in vivo models of human breast cancer. * to correlate response in this model to actual treatment outcome in patients, if the in vivo model is proven feasible. outline: previously collected breast tumor fragments are implanted into the renal capsule site of scid mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics. patients' medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment.

Eligibility criteria:
disease characteristics: * diagnosis of breast cancer * any stage of disease * primary or metastatic disease * human breast tumor tissues available after the diagnoses have been made * enrolled on the ongoing breast tissue repository trial vu-vicc-bre-03103 * have consented to the use of their tissues for research purpose * hormone receptor status not specified patient characteristics: * menopausal status not specified prior concurrent therapy: * not specified

Keywords: breast cancer
survivorship sleep program

Conditions: Cancer; Insomnia

Summary: this is a randomized pilot trial to test the feasibility and acceptability (primary outcomes) of a virtual cognitive behavioral program for insomnia for survivors of various cancer types. secondary outcomes are to examine the preliminary effects on reducing insomnia severity from baseline to post-intervention.

cognitive behavioral therapy for insomnia (cbt-i), is an evidenced-based insomnia program that is recommended by the american college of physicians and can be delivered using session-by-session treatment manuals. among cancer survivors, cbt-i has only yielded small-to-moderate sized improvements in several aspects of sleep, including sleep efficiency, sleep onset latency, and wake after sleep onset as compared with inactive control conditions. moreover, systematic reviews of cbt-i with cancer survivors have found high rates of attrition and low attendance. thus, while cbt-i for cancer survivors is promising, further adaptation is needed to demonstrate greater feasibility and larger effects. additionally, cbt-i is traditionally delivered in-person, which is not feasible for many cancer survivors. barriers include time limitations, travel, and illness burden constraints, as well as a paucity of trained cbt-i providers. telehealth delivery of cbt-i is an innovative approach to address these barriers to care and enhance uptake. the intervention being tested in this study was informed by a 4-10 session cbt-i protocol and adapted based on interviews the investigators conducted with cancer survivors with insomnia to learn about their sleep-related challenges, suggestions, and preferences for intervention delivery, as well as a systematic review and meta-analysis the investigators published in sleep medicine reviews in 2020. the research study procedures include screening for eligibility and randomization into 1 of 2 study arms: the adapted virtual intervention group or a control group (enhanced usual care; referral for behavioral sleep medicine and sleep hygiene handout). participants will be in this research study for approximately 2 months. it is expected that about 40 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * history of nonmetastatic, localized, or regional solid or blood malignancy(ies) * completion of primary cancer treatment (i.e., radiation, surgery, and/or chemotherapy) * chronic insomnia * age ≥18 years exclusion criteria: * self-reported inability to speak and write in english * undertreated noninsomnia sleep disorder (e.g., sleep apnea) * undertreated epilepsy, serious mental illness, or suicidality, and/or psychiatric hospitalization in the past year * unwilling or unable to discontinue night shift work

Keywords: insomnia cancer survivors
engaging religious leaders to reduce blood pressures in tanzanian communities

Conditions: Hypertension

Summary: the investigators hypothesize that communities in which religious leaders are provided with education about blood pressure and how to measure blood pressure will have lower overall average blood pressures than communities in which religious leaders do not receive education about blood pressure.

this research is being done to determine whether the religious engagement in health intervention can reduce community blood pressure. the study is being conducted in the northwestern tanzania. 20 communities will be involved: 10 will be randomized to the religious engagement in health intervention arm, and 10 will be randomized to the control arm. the religious engagement in health intervention includes the following three evidence-based components: (1) educational sessions for christian and muslim leaders on religious teachings and medical aspects of blood pressure, (2) equipping religious leaders to provide blood pressure teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community blood pressure screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.

Eligibility criteria:
inclusion criteria: * adult ≥35 years of age * has lived in the community for ≥1 year * household identified for random sampling is primary residence: has slept in the household at least once in the past 2 weeks and considers this their primary residence exclusion criteria: * first-degree relative from the same household already enrolled * relative of the same sex from the same household already enrolled

Keywords: religious leaders community engagement hypertension tanzania
a survey to evaluate early experience from patient and care partner on injection and device for kesimpta® indicated for multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this was a us-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with ms receiving kesimpta and care partners of patients with ms (formal or informal)receiving kesimpta.

the study aimed to enroll ninety-four (94) patients/care partners. the time period for enrollment was dependent on the uptake of kesimpta in the real-world. data collected for the study was obtained directly from the patient/care partner within the web-based database: de-identified data was stored on a secure server and transferred for analysis. responses from the patient and care partner surveys were pooled for analysis of study endpoints.

Eligibility criteria:
patients with ms inclusion criteria: * adult aged eighteen (18) years of age or over at the time of the survey * prescribed kesimpta within the prior 12 months and currently self-administering treatment using the sensoready® pen * ms diagnosis based on 2017 mcdonald criteria care partner inclusion criteria: * adult aged eighteen (18) years of age or over * formal or informal care partner of patient with ms prescribed kesimpta within the prior 12 months * is currently administering kesimpta using the sensoready® pen on their patient's behalf patients with ms exclusion criteria: * previously used injection as a part of inclusion in any ofatumumab (omb) randomized clinical trial * active hepatitis b virus (hbv) * cognitive impairment that would impact their ability to participate in a survey study

Keywords: multiple sclerosis ms nis kesimpta ofatumumab
influence of physical exercise on cognitive functioning of traumatic brain injury patients

Conditions: Brain Injuries; Brain Diseases; Central Nervous System Diseases; Craniocerebral Trauma; Trauma, Nervous System

Summary: the aim of this study is to determine the effects of an acute session of physical exercise on cognitive functioning and humor of traumatic brain injury patients and to investigate whether different cognitive responses can be achieved with different intensities of exercise (moderate and vigorous). the investigators hypothesize that while moderate intensity physical exercise may be beneficial to cognitive functioning, vigorous intensity may be detrimental to tbi patients, as physical fatigue may impair alertness and other higher cognitive functions.

it is well known the benefits of physical exercise to cognitive functioning, which have been demonstrated in animal studies and in those with healthy humans or with individuals with some type of pathology. nevertheless, there are few studies investigating the effects of acute physical exercise on cognitive functions of people with traumatic brain injury, even though they frequently have impairments in several cognitive domains due to their brain damage. the effect of two intensities of physical exercise (moderate and exhaustive) in attention, processing speed, memory, executive control and decision making will be investigated in patients with tbi. for that matter, their performance will be compared to non-brain injured subjects submitted to the same protocol and to tbi patients submitted to a stretching session. each subject will be submitted to a neuropsychological evaluation before and after the physical exercise in order to determine if there is an improvement in cognitive performance post-exercise.

Eligibility criteria:
patients with tbi eligible for participation in this research study must meet the following inclusion criteria: inclusion criteria: * diagnose of moderate to severe tbi * be at least six-months post-injury * have a neurologist that allowed to enroll into the study * be able to take part in a cycloergometer-protocol, attested by the laboratory (cepe) physician * brain injury must have occurred in adult life * provided written informed consent for participation exclusion criteria:

Keywords: tbi acute physical exercise cognitive functions mood
safety and efficacy of qbeco in moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of qbeco site specific immunomodulation for the induction of clinical response and remission in subjects with moderate to severe ulcerative colitis


Eligibility criteria:
inclusion criteria: * male or female subjects who have reached age of majority * willing to learn and able to self-administer study drug * diagnosis of uc established at least 6 months before screening visit, by clinical and endoscopic evidence. * currently experiencing moderate to severe active uc defined as a mayo score of 6-12 (inclusive) at screening. * endoscopic evidence of active mucosal disease, as assessed by flexible sigmoidoscopy, with an endoscopic finding sub-score of ≥2 at screening. * rectal bleeding sub-score of ≥1 at screening. * physician's global assessment sub-score of ≥2 at screening. * male/female subjects who agree to practice effective methods of contraception exclusion criteria: * history of colonic or rectal surgery other than hemorrhoid surgery or appendectomy * currently receiving total parenteral nutrition * disease limited to ulcerative proctitis * diagnosed with crohn's disease, indeterminate colitis, microscopic colitis or, ischemic or infectious colitis * known or suspected hypersensitivity to any component of the product * known human immunodeficiency virus (hiv) infection or other immunosuppressive disorder * concurrently participating in another study or receiving other experimental or investigational therapies within past 3 months * females who are currently pregnant or lactating * any history of malignancy. exceptions may apply for cervical cancer and some forms of skin cancer

Keywords: ulcerative colitis inflammatory bowel disease
effect of adding hyaluronidase to bupivacaine in transversus abdominis plane block for cesarean section

Conditions: Pain, Postoperative

Summary: since tap block needs to affect several nerves in single tissue plane with a single prick, hyaluronidase is expected to aid greatly in the spread of the la and help the block. however, there have not been adequate studies to establish the efficacy of adding hyaluronidase in lateral tap after cesarean section. hence, the present study was carried out to evaluate the efficacy of hyaluronidase in different concentrations added to bupivacaine in us-guided bilateral lateral tap block.


Eligibility criteria:
inclusion criteria: * parturients who aged between 18-40 years old * with asa physical status grade ii and * scheduled for elective cs under spinal anesthesia exclusion criteria: * patients with asa grade iii or iv, * refusal to participate, * emergency cs or complicated pregnancy, * those with bleeding disorders or on anticoagulants, * those with severe respiratory and cardiovascular diseases, * having any local infection at the injection site, * history of allergy to one of the used drugs, * obese patients (body mass index ≥ 30 kg/m2).